WHAT IS CLAIMED IS:

1. A compound having formula (I):



(I)

or a ~~including~~ hydrate~~s~~, solvate~~s~~, polymorph~~s~~, pharmaceutically acceptable salt~~s~~, prodrug~~s~~, ~~and~~ or complex~~es~~ thereof, wherein:

X^1 is selected from the group consisting of CR^4 and N;

X^2 is selected from the group consisting of CR^{4b} and N;

X^3 is selected from the group consisting of CR^{4c} and N;

R^1 is selected from the group consisting of optionally substituted C_{1-6} linear alkyl, optionally substituted C_{3-6} branched alkyl, optionally substituted C_{3-6} cyclic alkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted benzyl, optionally substituted heteroaryl methyl, ;

 , and  ;

R^2 is selected from the group consisting of hydrogen, $NR^{10a}R^{10b}$, fluorine, optionally substituted phenyl, optionally substituted heteroaryl, ,

 , and  ;



(II)

or a hydrate, solvate, polymorph, pharmaceutically acceptable salt, prodrug, or complex thereof~~including hydrates, solvates, polymorphs, pharmaceutically acceptable salts, prodrugs, and complexes thereof~~.

3. The compound of claim 1, wherein the compound is of formula (III)



(III)

or a hydrate, solvate, polymorph, pharmaceutically acceptable salt, prodrug, or complex thereof~~including hydrates, solvates, polymorphs, pharmaceutically acceptable salts, prodrugs, and complexes thereof~~.

4. The compound of claim 1, wherein the compound is of formula (IV)



(IV)

or a hydrate, solvate, polymorph, pharmaceutically acceptable salt, prodrug, or complex thereof~~including hydrates, solvates, polymorphs, pharmaceutically acceptable salts, prodrugs, and complexes thereof~~.

5. The compound of claim 1, wherein the compound is of formula (V)



(V)

or a hydrate, solvate, polymorph, pharmaceutically acceptable salt, prodrug, or complex thereof~~including hydrates, solvates, polymorphs, pharmaceutically acceptable salts, prodrugs, and complexes thereof~~.

6. The compound of claim 1, wherein the compound is of formula (VI)



(VI)

or a hydrate, solvate, polymorph, pharmaceutically acceptable salt, prodrug, or complex thereof~~including hydrates, solvates, polymorphs, pharmaceutically acceptable salts, prodrugs, and complexes thereof~~.

7. The compound of claim 1, wherein the compound is of formula (VII)



(VII)

or a hydrate, solvate, polymorph, pharmaceutically acceptable salt, prodrug, or complex thereof~~including hydrates, solvates, polymorphs, pharmaceutically acceptable salts, prodrugs, and complexes thereof~~.

8. The compound of claim 1, wherein the compound is of formula (VIII)



(VIII)

or a hydrate, solvate, polymorph, pharmaceutically acceptable salt, prodrug, or complex thereof~~including hydrates, solvates, polymorphs, pharmaceutically acceptable salts, prodrugs, and complexes thereof~~.

9. The compound of claim 1, wherein the compound is of formula (IX)



(IX)

or a hydrate, solvate, polymorph, pharmaceutically acceptable salt, prodrug, or complex thereof~~including hydrates, solvates, polymorphs, pharmaceutically acceptable salts, prodrugs, and complexes thereof~~.

10. The compound of claim 1, wherein the compound is of formula (X)



(X)

or a hydrate, solvate, polymorph, pharmaceutically acceptable salt, prodrug, or complex thereof~~including hydrates, solvates, polymorphs, pharmaceutically acceptable salts, prodrugs, and complexes thereof~~.

11. The compound of claim 1, wherein the compound is of formula (XI)



(XI)

or a hydrate, solvate, polymorph, pharmaceutically acceptable salt, prodrug, or complex thereof~~including hydrates, solvates, polymorphs, pharmaceutically acceptable salts, prodrugs, and complexes thereof~~.

12. The compound of claim 1, wherein the compound is of formula (XII)



(XII)

or a hydrate, solvate, polymorph, pharmaceutically acceptable salt, prodrug, or complex thereof~~including hydrates, solvates, polymorphs, pharmaceutically acceptable salts, prodrugs, and complexes thereof~~.

13. The compound of claim 1, wherein the compound is of formula (XIII)



(XIII)

or a hydrate, solvate, polymorph, pharmaceutically acceptable salt, prodrug, or complex thereof~~including hydrates, solvates, polymorphs, pharmaceutically acceptable salts, prodrugs, and complexes thereof~~.

14. The compound of claim 1, wherein the compound is of formula (XIV)



(XIV)

or a hydrate, solvate, polymorph, pharmaceutically acceptable salt, prodrug, or complex thereof~~including hydrates, solvates, polymorphs, pharmaceutically acceptable salts, prodrugs, and complexes thereof~~.

15. The compound of claim 1, wherein the compound is of formula (XV)



(XV)

or a hydrate, solvate, polymorph, pharmaceutically acceptable salt, prodrug, or complex thereof~~including hydrates, solvates, polymorphs, pharmaceutically acceptable salts, prodrugs, and complexes thereof~~.

16. The compound of claim 1, wherein the compound is of formula (XVI)



(XVI)

or a hydrate, solvate, polymorph, pharmaceutically acceptable salt, prodrug, or complex thereof~~including hydrates, solvates, polymorphs, pharmaceutically acceptable salts, prodrugs, and complexes thereof~~.

17. The compound of claim 1, wherein the compound is of formula (XVII)



(XVII)

or a hydrate, solvate, polymorph, pharmaceutically acceptable salt, prodrug, or complex thereof~~including hydrates, solvates, polymorphs, pharmaceutically acceptable salts, prodrugs, and complexes thereof~~.

18. The compound of claim 1, wherein the compound is

3-{2-[3-(methylsulfamoyl)phenyl]ethynyl}-2-(1H-pyrrol-1-yl)benzoic acid;

3 -[2-(1 H-indol-3-yl)ethynyl]-2-(1H-pyrrol-1-yl)benzoic acid;

3-[2-(3-methanesulfonamidophenyl)ethynyl]-2-(1H-pyrrol-1-yl)benzoic acid;

2-(lH-pyrrol-l-yl)-3-[2-(3-sulfamoylphenyl)ethynyl]benzoic acid;

3-[2-(3-carbamoylphenyl)ethynyl]-2-(1H-pyrrol-1-yl)benzoic acid;

3-(2-{imidazo[1,2-a]pyridin-6-yl}ethynyl)-2-(lH-pyrrol-1-yl)benzoic acid;

3-[2-(2-hydroxypyridin-4-yl)ethynyl]-2-(1H-pyrrol-l-yl)benzoic acid;

3-[2-(1H-indazol-6-yl)ethynyl]-2-(1H-pyrrol-1-yl)benzoic acid;

3-{2-[3-(3,3-dimethyl-2-oxoazetidin-1-yl)phenyl]ethynyl}-2-(lH-pyrrol-1-yl)benzoic acid;

3-(2-{3-[(2-carboxy-2,2-dimethylethyl)amino]phenyl}ethynyl)-2-(1H-pyrrol-1-yl)benzoic acid;

3-(2-{imidazo[1,2-a]pyrazin-3-yl}ethynyl)-2-(1H-pyrrol-1-yl)benzoic acid;

3-(2-{imidazo[1,2-a]pyridin-3-yl}ethynyl)-2-(1H-pyrrol-1-yl)benzoic acid;

3-(2-{imidazo[1,2-a]pyridin-5-yl}ethynyl)-2-(1H-pyrrol-1-yl)benzoic acid;

2-(1H-pyrrol-l-yl)-3-(2-{1H-pyrrolo[2,3-b]pyridin-5-yl}ethynyl)benzoic acid;

3-[2-(1-methyl-1H-indol-4-yl)ethynyl]-2-(1H-pyrrol-1-yl)benzoic acid;

3-[2-(1-methyl-1H-indol-5-yl)ethynyl]-2-(1H-pyrrol-l-yl)benzoic acid;

3-[2-(1-benzothiophen-6-yl)ethynyl]-2-(1H-pyrrol-1-yl)benzoic acid;

3-[2-(1H-indol-7-yl)ethynyl]-2-(1H-pyrrol-1-yl)benzoic acid;

3-{2-[2-(hydroxymethyl)phenyl]ethynyl}-2-(1H-pyrrol-1-yl)benzoic acid;

2-indol-1-yl-3-phenylethynyl-benzoic acid;
2-benzoimidazol-l-yl-3-pyridin-4-ylethynyl-benzoic acid;
or a pharmaceutically acceptable ~~form~~ salt, solvate or hydrate thereof.

19. A composition comprising at least one compound according to claim 1 and at least one excipient.

20. A composition comprising at least one compound according to claim 18 and at least one excipient.

21. ~~A method for treating or preventing a disease caused by EBNA1 activity, the method comprising administering to a subject an effective amount of at least one~~A compound according to claim 1 for use as a medicament.

22. The use of a compound according to claim 1 in the manufacture of a medicament for the treatment or prevention of a disease caused by EBNA1 activity.
~~22. The method of claim 21, wherein the at least one compound is administered in a composition further comprising at least one excipient.~~

~~23.~~23. The ~~method of~~ use according to claim ~~21~~ 22, wherein the disease caused by EBNA1 activity is cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis.

~~24. The method of claim 22, wherein the disease caused by EBNA1 activity is cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis.~~

~~25.~~24. The ~~method of~~ use according to claim 23, wherein the cancer is nasopharyngeal carcinoma, gastric carcinomas, non-hodgkin lymphoma, anaplastic large-cell lymphoma, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, B-cell lymphoma, Burkitt's lymphoma, reticuloendotheliosis, reticulosis, microglioma, diffuse large B-cell lymphoma, extranodal T/NK lymphoma/angiocentric lymphoma, follicular lymphoma, immunoblastic lymphoma, mucosa-associated lymphatic tissue lymphoma, B-cell chronic lymphocytic leukemia, mantle cell lymphoma, mediastinal large B cell lymphoma, lymphoplasmactic lymphoma, nodal marginal zone B cell lymphoma, splenic marginal zone lymphoma,

intravascular large B-cell lymphoma, primary effusion lymphoma, lyphomatoid granulomatosis, angioimmunoblastic lymphadenopathy, leiomyosarcomas, X-linked lymphoproliferative disease, post-transplant lymphoproliferative disorders, Hodgkin's lymphoma or breast cancer.

~~26. The method of claim 24, wherein the cancer is nasopharyngeal carcinoma, gastric carcinomas, non-hodgkin lymphoma, anaplastic large-cell lymphoma, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, B-cell lymphoma, Burkitt's lymphoma, reticuloendotheliosis, reticulosis, microglioma, diffuse large B-cell lymphoma, extranodal T/NK-lymphoma/angiocentric lymphoma, follicular lymphoma, immunoblastic lymphoma, mucosa-associated lymphatic tissue lymphoma, B-cell chronic lymphocytic leukemia, mantle cell lymphoma, mediastinal large B-cell lymphoma, lymphoplasmactic lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, lyphomatoid granulomatosis, angioimmunoblastic lymphadenopathy, leiomyosarcomas, X-linked lymphoproliferative disease, post-transplant lymphoproliferative disorders, Hodgkin's lymphoma or breast cancer.~~

~~27.~~25. ~~A method for treating or preventing Epstein-Barr Virus infection, the method comprising administering to a subject an effective amount of at least one~~The use of a compound according to claim 1 in the manufacture of a medicament for the treatment or prevention of Epstein-Barr Virus infection.

~~28. The method of claim 27, wherein the at least one compound is administered in a composition further comprising at least one excipient.~~

~~29.~~26. ~~A method for treating or preventing a disease or condition associated with Epstein-Barr Virus infection, the method comprising administering to a subject an effective amount of at least one~~The use of a compound according to claim 1 in the manufacture of a medicament for the treatment or prevention of a disease or condition associated with Epstein-Barr Virus infection.

~~30. The method of claim 29, wherein the at least one compound is administered in a composition further comprising at least one excipient.~~

~~31.~~27. ~~A method for treating lytic Epstein-Barr Virus infection, the method comprising administering to a subject an effective amount of at least one~~The use of a compound according to claim 1 in the manufacture of a medicament for the treatment of lytic Epstein-Barr Virus infection.

~~32. The method of claim 31, wherein the at least one compound is administered in a composition further comprising at least one excipient.~~

~~33.~~28. ~~A method for treating latent Epstein-Barr Virus infection, the method comprising administering to a subject an effective amount of at least one~~The use of a compound according to claim 1 in the manufacture of a medicament for the treatment of latent Epstein-Barr Virus infection.

~~34.~~29. The ~~method of~~ use according to any one of claim~~s~~ ~~33~~ 21 to 28, wherein the ~~at least one compound is administered in a composition~~ medicament further ~~comprising~~ comprises at least one excipient.